Acadia Pharmaceuticals (ACAD) PT Raised to $31 at Morgan Stanley
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $29.01 +2.73%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $31.00 (from $30.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
- JD Logistics Inc (2618:HK) (JDLGF) PT Lowered to HK$18 at Nomura/Instinet
- Info Edge India (INFOE:IN) PT Raised to INR1,260 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
